Analysts See $-0.38 EPS for Novan, Inc. (NOVN)

August 9, 2018 - By Margaret Guttierez

Analysts expect Novan, Inc. (NASDAQ:NOVN) to report $-0.38 EPS on August, 10.They anticipate $0.24 EPS change or 38.71 % from last quarter’s $-0.62 EPS. After having $-0.21 EPS previously, Novan, Inc.’s analysts see 80.95 % EPS growth. The stock decreased 1.08% or $0.03 during the last trading session, reaching $2.76. About 16,476 shares traded. Novan, Inc. (NASDAQ:NOVN) has declined 38.10% since August 9, 2017 and is downtrending. It has underperformed by 50.67% the S&P500.

Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide therapies in dermatology. The company has market cap of $71.87 million. The Company’s lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. It currently has negative earnings. The companyÂ’s product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology.

More important recent Novan, Inc. (NASDAQ:NOVN) news were published by: which released: “Stock investors rediscover defensives before trade war deadlines” on August 09, 2018, also published article titled: “Benzinga’s Daily Biotech Pulse: Merck’s Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile”, published: “New Novan incentive plan targets share price goals and $25M, $50M bonus pools” on August 08, 2018. More interesting news about Novan, Inc. (NASDAQ:NOVN) was released by: and their article: “More drugmakers build Brexit stockpiles as EU agency faces exodus” with publication date: August 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.